×
About 2,025 results

ALLMedicine™ Hyperoxaluria Center

Research & Reviews  983 results

A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large co...
https://doi.org/10.1016/j.kint.2021.03.031
Kidney International; Martin-Higueras C, Garrelfs SF et. al.

Apr 18th, 2021 - Outcome data in primary hyperoxaluria type 3 (PH3), described as a less severe form of the PH's with a low risk of chronic kidney disease, are scarce. To investigate this, we retrospectively analyzed the largest PH3 cohort reported so far. Of 95 p...

Transplantation outcomes in patients with primary hyperoxaluria: a systematic review.
https://doi.org/10.1007/s00467-021-05043-6 10.1038/nrneph.2012.113 10.1038/ki.2014.280 10.1038/ki.2014.222 10.1111/j.1600-6143.2010.03271.x 10.1056/NEJMra1301564 10.1093/ndt/gfs078 10.1111/j.1399-3046.2009.01230.x 10.1007/s004670100001 10.1007/s00467-003-1234-x 10.1016/s1569-9056(19)30291-x 10.1002/jrsm.41 10.1097/00007890-200209150-00020 10.1002/lt.24009 10.1016/j.kint.2019.08.018 10.1038/ki.2009.435 10.2215/cjn.07430711 10.1159/000086359 10.1046/j.1523-1755.1999.00619.x 10.1186/s12876-020-01349-1 10.1155/2015/634175 10.1097/TP.0b013e3181a27939 10.1111/petr.12595 10.1007/s00467-016-3324-6 10.1093/ndt/16.2.348 10.1046/j.1523-1755.1998.00876.x 10.1038/ki.1992.434 10.1111/petr.12705 10.1111/petr.13313 10.1111/ajt.12706 10.1038/sj.ki.5001758 10.12659/aot.882227 10.1097/01.Tp.0000084203.76110.Ac 10.1053/jlts.2001.28741 10.1002/lt.24167 10.1034/j.1399-3046.2000.00107.x 10.1111/petr.13406 10.1097/TP.0b013e3181a4e710 10.1093/ndt/gfq353 10.1007/s00467-017-3782-5 10.1111/petr.12376 10.1097/00007890-200108150-00012 10.1097/00007890-198806000-00031 10.1002/lt.24676 10.1034/j.1600-6143.2003.00050.x 10.1097/01.tp.0000225831.35143.06 10.1016/0002-9343(91)90539-A 10.1093/ndt/10.supp8.3 10.1016/s0022-3476(99)70095-8 10.1159/000086358 10.1093/ndt/6.7.502 10.1097/01.sla.0000133083.54934.ae 10.1093/ndtplus/sfq063 10.2215/CJN.06820613 10.1111/j.1523-1755.2004.00796.x 10.1111/petr.13457 10.1007/s00240-005-0495-1 10.1177/1536867X1801700402 10.1016/j.ekir.2020.09.022
Pediatric Nephrology (Berlin, Germany); Metry EL, van Dijk LMM et. al.

Apr 8th, 2021 - Primary hyperoxaluria type 1 (PH1) is characterized by hepatic overproduction of oxalate and often results in kidney failure. Liver-kidney transplantation is recommended, either combined (CLKT) or sequentially performed (SLKT). The merits of SLKT ...

Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluri...
https://doi.org/10.1016/j.urology.2021.03.014
Urology Shee K, Ahn J et. al.

Mar 28th, 2021 - Primary hyperoxaluria 1 (PH1) is a devastating condition involving recurrent urolithiasis, early end-stage renal disease and multisystemic deposition of calcium oxalate crystals. Treatment options for PH1 are limited, inevitably requiring transpla...

Combined liver kidney transplantation for primary hyperoxaluria type 1: Will there stil...
https://doi.org/10.1111/petr.14003
Pediatric Transplantation; Tandoi F, Cussa D et. al.

Mar 20th, 2021 - Combined liver-kidney transplantation is a therapeutic option for children affected by type 1 primary hyperoxaluria. Persistently high plasma oxalate levels may lead to kidney graft failure. It is debated whether pre-emptive liver transplantation,...

see more →

Guidelines  2 results

Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and ...
https://doi.org/10.1093/ndt/gfs078
Nephrology, Dialysis, Transplantation : Official Publicat... Cochat P, Hulton SA et. al.

May 1st, 2012 - Primary hyperoxaluria Type 1 is a rare autosomal recessive inborn error of glyoxylate metabolism, caused by a deficiency of the liver-specific enzyme alanine:glyoxylate aminotransferase. The disorder results in overproduction and excessive urinary...

OXLUMO™ (lumasiran) - Dosing and Admin Guide
https://www.oxlumohcp.com

Use the dosing and admin guide to learn which dosing regimen is right for your patients. Review dosing and administration for OXLUMO

see more →

Drugs  1 results see all →

Clinicaltrials.gov  1,013 results

A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large co...
https://doi.org/10.1016/j.kint.2021.03.031
Kidney International; Martin-Higueras C, Garrelfs SF et. al.

Apr 18th, 2021 - Outcome data in primary hyperoxaluria type 3 (PH3), described as a less severe form of the PH's with a low risk of chronic kidney disease, are scarce. To investigate this, we retrospectively analyzed the largest PH3 cohort reported so far. Of 95 p...

Transplantation outcomes in patients with primary hyperoxaluria: a systematic review.
https://doi.org/10.1007/s00467-021-05043-6 10.1038/nrneph.2012.113 10.1038/ki.2014.280 10.1038/ki.2014.222 10.1111/j.1600-6143.2010.03271.x 10.1056/NEJMra1301564 10.1093/ndt/gfs078 10.1111/j.1399-3046.2009.01230.x 10.1007/s004670100001 10.1007/s00467-003-1234-x 10.1016/s1569-9056(19)30291-x 10.1002/jrsm.41 10.1097/00007890-200209150-00020 10.1002/lt.24009 10.1016/j.kint.2019.08.018 10.1038/ki.2009.435 10.2215/cjn.07430711 10.1159/000086359 10.1046/j.1523-1755.1999.00619.x 10.1186/s12876-020-01349-1 10.1155/2015/634175 10.1097/TP.0b013e3181a27939 10.1111/petr.12595 10.1007/s00467-016-3324-6 10.1093/ndt/16.2.348 10.1046/j.1523-1755.1998.00876.x 10.1038/ki.1992.434 10.1111/petr.12705 10.1111/petr.13313 10.1111/ajt.12706 10.1038/sj.ki.5001758 10.12659/aot.882227 10.1097/01.Tp.0000084203.76110.Ac 10.1053/jlts.2001.28741 10.1002/lt.24167 10.1034/j.1399-3046.2000.00107.x 10.1111/petr.13406 10.1097/TP.0b013e3181a4e710 10.1093/ndt/gfq353 10.1007/s00467-017-3782-5 10.1111/petr.12376 10.1097/00007890-200108150-00012 10.1097/00007890-198806000-00031 10.1002/lt.24676 10.1034/j.1600-6143.2003.00050.x 10.1097/01.tp.0000225831.35143.06 10.1016/0002-9343(91)90539-A 10.1093/ndt/10.supp8.3 10.1016/s0022-3476(99)70095-8 10.1159/000086358 10.1093/ndt/6.7.502 10.1097/01.sla.0000133083.54934.ae 10.1093/ndtplus/sfq063 10.2215/CJN.06820613 10.1111/j.1523-1755.2004.00796.x 10.1111/petr.13457 10.1007/s00240-005-0495-1 10.1177/1536867X1801700402 10.1016/j.ekir.2020.09.022
Pediatric Nephrology (Berlin, Germany); Metry EL, van Dijk LMM et. al.

Apr 8th, 2021 - Primary hyperoxaluria type 1 (PH1) is characterized by hepatic overproduction of oxalate and often results in kidney failure. Liver-kidney transplantation is recommended, either combined (CLKT) or sequentially performed (SLKT). The merits of SLKT ...

Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluri...
https://doi.org/10.1016/j.urology.2021.03.014
Urology Shee K, Ahn J et. al.

Mar 28th, 2021 - Primary hyperoxaluria 1 (PH1) is a devastating condition involving recurrent urolithiasis, early end-stage renal disease and multisystemic deposition of calcium oxalate crystals. Treatment options for PH1 are limited, inevitably requiring transpla...

Combined liver kidney transplantation for primary hyperoxaluria type 1: Will there stil...
https://doi.org/10.1111/petr.14003
Pediatric Transplantation; Tandoi F, Cussa D et. al.

Mar 20th, 2021 - Combined liver-kidney transplantation is a therapeutic option for children affected by type 1 primary hyperoxaluria. Persistently high plasma oxalate levels may lead to kidney graft failure. It is debated whether pre-emptive liver transplantation,...

see more →

News  15 results

Fast Five Quiz: Primary Hyperoxaluria Type 1 Management
https://reference.medscape.com/viewarticle/944415

Feb 28th, 2021 - Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disease that is caused by a functional defect of alanine:glyoxylate aminotransferase catalysis, resulting in the overproduction of oxalate. The clinical impact of PH1 can be devastat...

Fast Five Quiz: Primary Hyperoxaluria Type 1 Screening and Diagnosis
https://reference.medscape.com/viewarticle/944411

Feb 28th, 2021 - Primary hyperoxaluria (PH) encompasses a group of rare genetic metabolic disorders that are characterized by the accumulation of oxalate in the kidneys and other organs. PH is categorized as type 1 (PH1), type 2 (PH2) or type 3 (PH3). An estimated...

FDA Clears First Drug to Treat Ultra-Rare Metabolic Disorder
https://www.medscape.com/viewarticle/941520

Nov 23rd, 2020 - The US Food and Drug Administration (FDA) has approved lumasiran (Oxlumo, Alnylam Pharmaceuticals) subcutaneous injection to treat children and adults with primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder that causes recurrent ki...

Urinary Oxalate and CKD Progression: Is There an Association?
https://www.medscape.com/viewarticle/912061

May 1st, 2019 - Does higher urinary oxalate excretion predispose patients to kidney failure? Elevated levels of oxalate, a metabolite eliminated through the kidney, can be toxic. Oxalate nephropathy is characterized by high concentrations of oxalate in kidney tub...

FDA Approves First Drug to Treat Rare Metabolic Disorder
http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-rare-metabolic-disorder

For Immediate Release: November 23, 2020 Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is a cumulation of the work of ...

see more →

Patient Education  11 results see all →